Best Plasma Exchange Doctors Worldwide — TOP 16

Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.

Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.

Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.

Dr. Hana Golan heads the Pediatric Hemato-Oncology and Bone Marrow Transplantation Division at Sheba Medical Center. She specializes in high-risk pediatric tumors and complex childhood cancers. Dr. Golan serves as the principal investigator for the High-Risk Neuroblastoma ESIOP protocol. She practices at a hospital ranked among the global top 10 by Newsweek.

• National coordinator of multicenter oncology protocols and international Phase I/II clinical trials.
• Performs bone marrow transplants and CAR T-cell therapy for pediatric patients.
• Expert in neuroblastoma, leukemia, and treatment-resistant malignancies.
• Senior Lecturer at the Sackler Faculty of Medicine at Tel Aviv University.

Professor Xiao Yueyong is Chief Physician in the Department of Radiological Diagnosis at the Chinese PLA General Hospital. He is a leading expert in minimally invasive interventional oncology. He serves as the inaugural President of WATA (2025–). He is President of the International (2020–) and Asian (2012–) Societies of Cryotherapy. He is also Deputy Head of the NHC Expert Group on tumour ablation regulations (2009–).

He has performed over 100,000 CT/MRI‑guided minimally invasive procedures. His work covers chemical ablation, RFA, MWA, cryoablation, and NanoKnife (IRE). He introduced and advanced NanoKnife ablation in China. He led the first national standards for tumour cryoablation and NanoKnife.

Honors include the National Special Contribution Award (Lifetime Honorary). He received First Prize from the Chinese Medicine Education Association (2021). He received two Second Prizes for Military Medical Achievements (2016, 2018) and two Second Prizes from the China Anti‑Cancer Association (2019, 2022). He was named Asian Ablation Master. His research record includes 13 Chinese patents. He is the principal investigator for four NSFC projects and one MOST subject. He has published over 200 papers, with over 110 as first or corresponding author and over 40 in SCI journals. He has led over 10 ablation guidelines or consensus statements.

Dr. Ding Yi is the Associate Chief Physician in Hematology at Shanghai Tongji Hospital. She is also the acting deputy director of the Blood Transfusion Department. She holds a Master of Medicine from Tongji University. She serves on the Youth Committee of the Shanghai Society of Hematology.

She is skilled in diagnosing and treating leukemia, lymphoma, and myeloma. She offers hematopoietic and umbilical cord blood stem cell therapies. She specializes in acute leukemia. She developed sequential treatment protocols. She participated in research that won the Second Prize of the Shanghai Science and Technology Progress Award. She has published more than 10 papers.

Prof. Zhang Yan Lin – leading nephrologist with 30+ years focused on complex kidney conditions at Xiamen Humanity Hospital.

• Principal investigator for National Natural Science Foundation projects
• Specializes in lupus nephritis and vasculitis-related kidney impairment
• Deputy Chairperson of Asia-Pacific immunology academy's nephrology branch
• Author of 30+ publications including 6 SCI-indexed papers

Dr. Pazit Beckerman is the head of the Israeli Dialysis Registry. She works at Sheba Medical Center, a hospital ranked 7th globally. She specializes in chronic kidney disease and complex dialysis management. Dr. Beckerman completed a postdoctoral fellowship at the University of Pennsylvania.

• Served as Acting Director of Nephrology at Sheba Medical Center.
• Treats acute kidney injury and hypertension-related renal disease.
• Expert in glomerular diseases, protein loss, and electrolyte disorders.
• Board member of the Israeli Society of Nephrology and Hypertension.

Dr. Avichai Shimoni is the Director of Bone Marrow Transplantation at Sheba Medical Center. He treats complex blood cancers. He completed a specialized fellowship at the MD Anderson Cancer Center. Dr. Shimoni uses allogeneic and autologous transplants for high-risk patients. He is a professor and Chairman of Hematology at Tel Aviv University.

• Named among Israel’s Best Doctors by Forbes for 2025 and 2026.
• Authored over 250 scientific papers on cellular therapies and transplantation.
• Provides CAR T-cell therapy for leukemia, lymphoma, and multiple myeloma.
• Works at Sheba Medical Center, a top-10 hospital globally per Newsweek.

Dr. Elad Jacoby is a pioneer of pediatric CAR T–cell therapy in Israel. He heads the Pediatric Cell Therapy Center at Sheba Medical Center. Dr. Jacoby specializes in treating relapsed and high-risk pediatric leukemias and lymphomas. He completed fellowships at Johns Hopkins and the U.S. National Cancer Institute.

• Medical Director of the Advanced Biotherapy Center at Sheba Medical Center.
• Authored over 240 scientific publications in pediatric hemato-oncology.
• Board-certified in both Pediatrics and Pediatric Hematology and Oncology.
• Leads the integration of CAR T–cell therapy with bone marrow transplantation.

Dr. Pnina Langevich leads the National Center for Rheumatology at Sheba Medical Center. She is a former Vice President of the World Association of Rheumatologists. Forbes Israel has repeatedly named her among the country’s top doctors. Dr. Langevich treats severe cases of lupus, scleroderma, and rheumatoid arthritis.

• Served for 12 years as Vice President of the World Association of Rheumatologists.
• Functions as the Editor–in–Chief of the international medical journal Lupus.
• Specializes in managing treatment–resistant autoimmune and joint diseases.
• Works at Sheba Medical Center, ranked 7th worldwide by Newsweek in 2026.

Dr. Abraham Avigdor is the Director of the Institute of Hematology at Sheba Medical Center. He is a global authority on lymphoma, CAR-T therapy, and complex blood cancers. Dr. Avigdor founded the Israeli Lymphoma Working Group. He helps lead a clinic ranked 7th worldwide by Newsweek in 2026.

• Authored over 130 scientific publications on hemato-oncology and cellular therapy.
• Pioneered the integration of CAR-T cell therapy for lymphoma and myeloma.
• Leads allogeneic and autologous bone marrow transplantation programs.
• Served as the Chairman of the Israeli Lymphoma Study Group.

Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.

1980–1985: Completed doctoral studies at Nagasaki University, Japan

1968–present: Department of Radiology, Chinese PLA General Hospital

1988: Third Prize of the Military Science and Technology Progress Award

1989–present: Member of Radiological Society of North America(RSNA)

1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA

1991: Second Prize of the Military Science and Technology Progress Award

1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology

1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

1993: Granted the Lifetime Special Government Allowance of the State Council

1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology

1994: Third Prize of the Military Science and Technology Progress Award

1997: Second Prize of the Military Science and Technology Progress Award

1997–2009: Standing Member of Chinese Society of Radiology

1999: Third Prize of the Military Science and Technology Progress Award

1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology

2002: Second Prize of the Military Science and Technology Progress Award

2005: Third Prize of the Military Science and Technology Progress Award

Member of Radiological Society of North America(RSNA)

Standing Member of Chinese Society of Radiology

Group Leader of the Group of Intervention of Chinese Journal of Radiology

Deputy Director Member of Chinese Society of Interventional Oncology

Director Member of Beijing Medical Association Society of Interventional Radiology

Deputy Chief Editor of Chinese Journal of Medical Image Technology

Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army

Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

Awarded the Special Government Allowance of the State Council

Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.

Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”

Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.

In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.

Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.

In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.

Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.

From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.

Professor Zhang Jinshan’s Academic Achievements

Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.

Selected Publications by Professor Zhang Jinshan

1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.

Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.

2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.

Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.

3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.

Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.

4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.

Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.

5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.

Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.

6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.

Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.

7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.

Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.

8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.

Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.

Professor Zhang Jinshan co-authored monographs

1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.

2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.

3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.

Professor Zhang Jinshan’s Research project

1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.

2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.

3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.

4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.

Dr. Jair Bar is a thoracic oncologist and Deputy Director of the Cancer Center at Sheba Medical Center. He specializes in treating advanced non-small cell lung cancer using personalized immunotherapy and targeted treatments. Dr. Bar holds a PhD in Molecular Biology and leads a research lab focused on immunotherapy resistance.

• Chair of the Israel Lung Cancer Group.
• Board-certified in both Medical Oncology and Radiotherapy Oncology.
• Treats patients at Sheba Medical Center, a top-10 globally ranked hospital.
• Uses molecular and genetic profiling to create precise cancer treatment plans.

Dr. Kadri Yamac is an internist and hematologist. He earned his medical degree from Ankara University Faculty of Medicine (1976–1982). He completed Internal Medicine training at Gazi University Faculty of Medicine (1984–1989). He then completed a Hematology subspecialty at Gazi University Faculty of Medicine (1990–1993). He became an Associate Professor at Gazi University Faculty of Medicine in 1995. He was promoted to Professor in 2002.

Medical interests: anemias, coagulation disorders, hemochromatosis, chronic lymphocytic leukemia, lymph node diseases, non-Hodgkin lymphoma, Hodgkin lymphoma.

Prof. Dr. Salih Pay is a rheumatology specialist and professor. He has been a professor since 2008. He graduated from GATA Gülhane Military Medical Faculty in 1987. He completed his internal medicine residency at GATA in 1995. He finished rheumatology training at Hacettepe University from 1996 to 1998. He served as an assistant professor at GATA from 1999 to 2000. He became an associate professor in 2000. He conducted experimental research on chemokines and chemokine receptors at the UC San Diego – Stein Research Center from 2001 to 2002. He has published nearly 100 scientific articles.

He currently practices at Koru Ankara Hospital. His focus is on rheumatic diseases. These include rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, scleroderma, vasculitis, Behçet's disease, gout, and osteoporosis.

Dr. Eyup Koc is an internist and nephrologist. He studied at Istanbul University – Cerrahpaşa Faculty of Medicine from 1980 to 1986. He completed his residency in Internal Medicine at Izmir Atatürk Training and Research Hospital from 1989 to 1994. He then specialized in Nephrology at Gazi University Faculty of Medicine from 2005 to 2008.

Clinical interests include hypertension, acute kidney failure, chronic kidney failure, hemodialysis, peritoneal dialysis, kidney transplantation, glomerulonephritis, and diabetic kidney disease.